progastrin releasing peptide pro-gastrin - Pro GRP tumor marker Progastrin Progastrin Releasing Peptide: A Crucial Biomarker in Disease Diagnosis

Pro GRP tumor marker Progastrin releasing peptide (ProGRP), a significant precursor to the neuropeptide gastrin-releasing peptide (GRP), has emerged as a critical biomarker in the medical field, particularly in the diagnosis and monitoring of certain cancers. This peptide is synthesized as a larger precursor molecule and is subsequently cleaved to form the active releasing peptide. Understanding the role and significance of ProGRP is vital for healthcare professionals and researchers alike.

Understanding Progastrin Releasing Peptide

Pro-gastrin-releasing peptide is a protein that plays a role in various biological processes. It is the precursor of gastrin-releasing peptide, a hormone that stimulates the secretion of gastrin, thereby increasing gastric acid acidity. ProGRP itself, however, has gained prominence primarily as a tumor markerPro-gastrin-releasing-peptide. Its expression is notably elevated in certain types of neuroendocrine tissue differentiation, making it a valuable indicator in specific clinical contexts. The Pro-gastrin molecule, as a precursor, holds key information about the production and potential pathology related to GRPPro-gastrin-releasing peptide in patients with benign and ....

ProGRP as a Biomarker for Small Cell Lung Cancer (SCLC)

The most well-established application of ProGRP is its use as a biomarker for small cell lung cancer (SCLC). Numerous studies have demonstrated that serum ProGRP levels are significantly elevated in patients with SCLC作者：B Nisman·2015·被引用次数：1—Abstract. 7570. Background:Pro-gastrin-releasing peptide(proGRP) is a precursor of the neuropeptide hormone produced by small cell lung cancer .... This makes ProGRP a sensitive and specific marker for this aggressive form of lung cancer, often outperforming other established tumor markers such as neuron-specific enolase (NSE).Pro-gastrin-releasing peptide (ProGRP) as a biomarker in ...

Research has shown that ProGRP can be a more sensitive and specific biomarker of SCLC than NSE. The ProGRP blood test is frequently utilized to aid in the diagnosis, treatment monitoring, and assessment of treatment response in SCLC patients. For instance, studies have indicated that ProGRP results can correlate with tumor extension in SCLC, with higher sensitivity in extensive disease compared to limited disease. The ProGRP tumor marker is considered to be a sensitive tumor biomarker for SCLCPro-Gastrin-Releasing Peptide as a Biomarker in Lung ....

Furthermore, ProGRP has also been investigated for its potential role in identifying well-differentiated neuroendocrine tumors (WDNETs), including bronchopulmonary carcinoids.作者：E Wojcik·2017·被引用次数：83—Pro-gastrin-releasing peptide(ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response ... An elevated ProGRP level can serve as a strong indication for a primary tumor in certain contexts, contributing to differential diagnosis.Associations between progastrin-releasing peptide (ProGRP ...

Beyond SCLC: ProGRP in Other Conditions

While SCLC is the primary focus, research suggests that ProGRP levels can be increased in a variety of benign and malignant diseases. This indicates that ProGRP might not be exclusively indicative of SCLC and can be influenced by other conditionsProgastrin-releasing peptide as a diagnostic and therapeutic ....

For example, studies have compared serum ProGRP concentrations in patients with pneumonia, chronic obstructive pulmonary disease (COPD), and early-stage lung cancerPro-Gastrin-Releasing Peptide as a Biomarker in Lung .... Some findings suggest that concentrations of proGRP in pneumonia and COPD patients can be higher than in early stages of adenocarcinoma (ADC) and squamous cell carcinoma (SQCC). This highlights the importance of considering the clinical context when interpreting ProGRP levels.

Additionally, elevated ProGRP levels have been observed in other malignant conditions, prompting investigations into its broader diagnostic utility. The Pro-gastrin precursor's role in these varied disease states is an ongoing area of research.作者：Z Gong·2016·被引用次数：21—ProGRP is a signalpeptidethat is commonly produced by SCLC. Serum ProGRP is considered to be a sensitive tumor biomarker for SCLC.

Technical Aspects and Diagnostic Considerations

The measurement of ProGRP is typically performed through blood tests. The ProGRP normal range can vary slightly between laboratories, but generally, elevated levels are considered significant.Circulating progastrin-releasing peptide in the diagnosis of ... For instance, median ProGRP concentrations in benign conditions, other malignancies, or non-small cell lung cancer (NSCLC) are reported to be lower compared to SCLC.

The Pro-gastrin releasing peptide (31-98) fragment has been identified as a specific product of SCLC cells作者：M Grønberg·2025·被引用次数：1—Progastrin-releasing peptide(ProGRP) is a more sensitive and specific biomarker of SCLC than neuron-specific enolase (NSE). We investigated .... Sophisticated assays, such as the Elecsys® platform, are being developed and evaluated for their accuracy in measuring plasma ProGRP. These advancements aim to improve the reliability and standardization of ProGRP testing.

It is important to note that while Pro-gastrin-releasing peptide is a valuable biomarker, histopathology from biopsy or cytology remains the gold standard for definitive diagnosis of SCLC. However, ProGRP assays provide crucial supporting information for diagnosis, staging, and monitoring treatment efficacy. ProGRP and NSE levels are considered of paramount significance for the clinical diagnosis and staging of SCLC patients.

Future Directions

The continued research into ProGRP holds promise for expanding its diagnostic and therapeutic applications. Investigations are exploring its role not only as a diagnostic marker but also as a potential therapeutic target作者：HJ Oh·2016·被引用次数：47—Background:Progastrin-releasing peptide(proGRP) is a recently identified biomarker of small cell lung cancer (SCLC). We evaluated the usefulness of plasma .... The complex interplay of gastrin, peptide signaling, and releasing peptide mechanisms suggests that further understanding of ProGRP could lead to novel treatment strategies2024年12月15日—The objective of this study was to compare serum proGRP concentration in pneumonia, chronic obstructive pulmonary disease (COPD) and early-stage primary lung .... The investigation into progastrin and its related peptide forms continues to be a vital area in medical research.作者：G Begolli·2025·被引用次数：2—Conclusions: Concentrations of proGRP in pneumonia and COPD patients were higher than in patients in the ADC and SQCC early stages and could ...